BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., headquartered in Novato, California, is a global biotechnology company that focuses relentlessly on developing and commercializing highly innovative therapies for people with serious and life-threatening rare genetic diseases. Founded in 1997, BioMarin has built a remarkable legacy in the orphan drug space, particularly in the highly specialized field of enzyme replacement therapies (ERTs).

The company has successfully developed and launched multiple first-in-class treatments for devastating metabolic conditions such as Mucopolysaccharidosis (MPS) types I, IVA, and VI, as well as Phenylketonuria (PKU). Beyond ERTs, BioMarin has significantly expanded its scientific capabilities into advanced therapeutic modalities.

They developed Voxzogo, the first approved medical treatment for achondroplasia (the most common form of dwarfism), which targets underlying bone growth pathways. Furthermore, BioMarin achieved a monumental medical milestone with the development of Roctavian, the first approved gene therapy for severe hemophilia A, offering the potential for a functional cure through a single infusion.

The organization operates sophisticated biologic and gene therapy manufacturing facilities globally, including its massive campus in Novato and facilities in Ireland. BioMarin is characterized by its deep, patient-centric culture, working intimately with patient advocacy groups to understand the daily struggles of those living with ultra-rare diseases.

Through specialized, high-impact science and a commitment to global access, BioMarin remains a beacon of hope for patients suffering from genetic conditions previously considered untreatable.